

# Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

## Anti-NAT10 antibody [EPR18663]

RRID:AB\_3696046

Type: Antibody

### Proper Citation

Abcam Cat# ab194297, RRID:AB\_3696046

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_3696046](http://antibodyregistry.org/AB_3696046)

**Proper Citation:** Abcam Cat# ab194297, RRID:AB\_3696046

**Target Antigen:** NAT10

**Host Organism:** Rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P

**Antibody Name:** Anti-NAT10 antibody [EPR18663]

**Description:** This recombinant monoclonal targets NAT10

**Target Organism:** rat, mouse, human

**Clone ID:** EPR18663

**Antibody ID:** AB\_3696046

**Vendor:** Abcam

**Catalog Number:** ab194297

**Record Creation Time:** 20250820T021822+0000

**Record Last Update:** 20250820T131436+0000

### Ratings and Alerts

No rating or validation information has been found for Anti-NAT10 antibody [EPR18663].

No alerts have been found for Anti-NAT10 antibody [EPR18663].

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Wang Y, et al. (2026) NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin. iScience, 29(1), 114488.

Shao J, et al. (2026) N-acetyltransferase 10 regulates chemokine expression in keratinocytes and promotes atopic dermatitis. Cell chemical biology.

Li H, et al. (2025) Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. iScience, 28(7), 112860.